Alto Neuroscience Q1 net loss $15.2M; cash $161.3M; key trial readouts on track

Alto Neuroscience, Inc.

2025-Q1 EPS reported -$0.56

Net loss of $15.2M for Q1 2025 vs $13.4M in Q1 2024; R&D expense flat at $10.0M.
Cash, cash equivalents and restricted cash of $161.3M as of March 31, 2025, expected to fund operations into 2028.
ALTO-203 Phase 2 POC MDD trial topline data expected in Q2 2025; ALTO-101 Phase 2 CIAS data in H2 2025.
ALTO-300 Phase 2b MDD trial data expected mid-2026; ALTO-100 Phase 2b BPD trial data H2 2026.
At annual meeting, stockholders reelected Husseini Manji as Class I director and ratified Deloitte as auditor.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.